Plaque Psoriasis Treatment Market Size, Share, Growth, and Outlook (2025-2033)

Plaque Psoriasis Treatment Market Overview

The plaque psoriasis treatment market is currently valued at USD 12.7 billion in 2024. This market has experienced significant growth over the past few years, driven by increasing prevalence and advancements in treatment options. Historically, the market has shown robust expansion, with a compound annual growth rate (CAGR) of 8.89% from 2025 to 2033.

The market is projected to continue its upward trajectory, with expectations to reach substantial new heights by 2035. The growth is fueled by the rising adoption of innovative medications, increasing regulatory approvals, and a surge in clinical trials for advanced therapies. Additionally, the market is characterized by a strong presence of key players and a growing emphasis on telehealth services, which have become more prevalent post-pandemic. The future projections indicate a promising outlook for the plaque psoriasis treatment market, with a continued focus on developing novel drugs and therapies to meet the unmet needs of patients worldwide. 

Plaque psoriasis also known as psoriasis vulgaris is a long-lasting and chronic autoimmune skin disease that causes cells to reproduce very quickly. It’s the most common type of psoriasis that causes thick, scaly patches called plaques on the skin. Typically, new skin cells grow every 28 to 30 days. But in the case of plaque psoriasis, new cells grow and move to the skin's surface every three to four days. The buildup of new cells replacing old cells creates plaques.

Moreover, plaque psoriasis isn’t contagious. There is no cure for plaque psoriasis, but many treatment options are available, depending on the individual and the severity of symptoms. Topical therapy includes the use of emollients and moisturizers, corticosteroids, keratolytics, coal tar, anthralin, vitamin D3 analogs and calcineurin inhibitors. A combination of topical agents is sometimes more effective than when the drugs are used alone. Phototherapy is also most commonly used in the treatment.

Plaque Psoriasis Treatment Market Scope

To Know More Insights - Download Sample

Plaque Psoriasis Treatment Market Dynamics

Increasing adoption of innovative medications

The increasing adoption of innovative medications for plaque psoriasis is expected to drive the market over the forecast period. The development of innovative medications aims to address unmet needs and results in better disease management. In recent years, biosimilars are most focused in the treatment of plaque psoriasis, because biosimilars offers a wide range of benefits and require much less research and development than their reference biologics. Biosimilars are much cheaper to produce. 

For instance, on January 06, 2023, Alvotech and Teva Pharmaceuticals cleared that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application for AVT04, Alvotech’s proposed biosimilar to Stelara (ustekinumab). STELARA (ustekinumab) is indicated for the treatment of patients 6 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Moreover, many regulatory approvals such as FDA approvals increase the adoption of innovative medications by boosting the trust in patients about the safety of the medications. For instance, on September 09, 2022, Bristol Myers Squibb released that the U.S. Food and Drug Administration (FDA) approved Sotyktu(deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Additionally, on June 1, 2021, Novartis, a leader in immuno-dermatology and rheumatology, cleared the U.S. Food and Drug Administration (FDA) approval of Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for systemic therapy or phototherapy. This is the first approval for Cosentyx in a pediatric population in the US. 

Further, the increasing prevalence of plaque psoriasis, rising regulatory approvals, increasing clinical trials for advanced therapies, increasing awareness and early detection and technological advancements in the development of novel drugs and therapies are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications and side effects associated with the high doses of topical corticosteroids and other drugs,  the high cost of the treatment phototherapy and the lack of better and accurate treatment are expected to hamper the market. 

Plaque Psoriasis Treatment Market Segment Analysis

The global plaque psoriasis treatment market is segmented based on disease type, treatment type, sales channel and region.

The topical medications segment accounted for approximately 41.1% of the plaque psoriasis treatment market share

The topical medications segment is expected to hold the largest market share over the forecast period. Usually, there is no cure for plaque psoriasis, but topical medications are considered first-line therapeutics based on the severity and symptoms. Various types of topical medications such as anthralin, roflumilast (zoryve), corticosteroids, tapinarof (VTAMA), salicylic acid, coal tar, zinc pyrithione  and topical emollients are most commonly used for the treatment. 

For instance, on May 24, 2022, Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, cleared the U.S. Food and Drug Administration (FDA) approval of VTAMA (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults. This approval makes VTAMA cream the first and only FDA-approved steroid-free topical medication in its class.

Moreover, on July 29, 2022, Arcutis Biotherapeutics, Inc. cleared the U.S. Food and Drug Administration (FDA) approval of the New Drug Application for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The first and only topical phosphodiesterase-4 (PDE4) inhibitor approved for the treatment of plaque psoriasis, ZORYVE provides rapid clearance of psoriasis plaques and reduces itch in all affected areas of the body.

Further, their wide availability, acceptability, and, ease of application helps to hold the largest market share. The topical medications manage skin symptoms and have anti-inflammatory effects on the skin to clear psoriasis plaques. They include a class of medication called a corticosteroid. Although they are effective and fast-acting for better patient outcomes. In addition, their wide adoption also increases the demand for topical medications. 

Plaque Psoriasis Treatment Market Geographical Share

North America accounted for approximately 40.1% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing adoption of novel medications. North America especially in the United States has a strong presence of major players such as pharmaceutical companies, biotechnology companies and medical device companies. This presence of major players actively performs in research activities for the development of more advanced and effective therapeutics for the treatment of plaque psoriasis.

For instance, on December 20, 2021, Amgen released the U.S. Food and Drug Administration (FDA) approval of Otezla (apremilast) for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. With this expanded indication, Otezla is now the first and only oral treatment approved in adult patients with plaque psoriasis across all severities, including mild, moderate and severe.

Furthermore, due to the increasing prevalence of the condition, there is an increasing adoption of novel medications in the region. For instance, according to the National Psoriasis Foundation/USA, more than 8 million people in the U.S. have psoriasis. About eight in 10 people with psoriasis have plaque psoriasis. The increasing prevalence is increasing the demand for the adoption of novel therapeutics for the early management of the condition and associated severity for the better patient outcomes.

Plaque Psoriasis Treatment Market Companies

The major global players in the plaque psoriasis treatment market include Dermavant Sciences, Inc., Novartis AG, Pfizer Inc., Mylan N.V., Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca PLC, Lupin Pharmaceuticals, Inc., Bristol-Myers Squibb Company, AbbVie Inc., Eli Lilly and Company and among others. 

Recent Developments

• Icotrokinra - an oral IL-23 receptor inhibitor from Johnson & Johnson (in partnership with Protagonist Therapeutics) - showed strong Phase III results vs placebo and even outperformed an existing approved drug in head-to-head trials.
• Pecondle (also known as picankibart) - an anti-IL-23p19 biologic from Innovent Biologics - recently got regulatory approval in China for moderate-to-severe plaque psoriasis.
• ZORYVE cream / ZORYVE foam - a PDE-4 inhibitor topical therapy from Arcutis Biotherapeutics - continues to see rising demand. Its foam formulation (for scalp/body psoriasis) received FDA approval earlier this year and sales/use are reportedly growing.

Recent FDA Approvals / Regulatory Milestones

• Tremfya (guselkumab) - On 29 September 2025, the U.S. Food and Drug Administration (FDA) approved Tremfya for pediatric plaque psoriasis and active psoriatic arthritis in children aged 6 years or older (≥ 40 kg).

• ZORYVE (roflumilast) 0.3% - In May 2025, FDA approved ZORYVE topical cream 0.3% for plaque psoriasis (including intertriginous areas) in patients age 6 years and older.

   

Near-Term / Pending Updates to Watch

• The manufacturer of ZORYVE submitted a supplemental New Drug Application (sNDA) for roflumilast cream 0.3% to expand indication to children aged 2 to 5 years. FDA has accepted this sNDA (as of November 2025) - decision expected around mid-2026.

• Another drug, Icotrokinra (an oral IL-23 receptor inhibitor), is currently under FDA review. If approved, it could add a new oral option to the plaque-psoriasis treatment arsenal.

   

Why Purchase the Report?

• To visualize the global plaque psoriasis treatment market segmentation based on disease type, treatment type, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of plaque psoriasis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global plaque psoriasis treatment market report would provide approximately 61 tables, 59 figures, and 187 Pages.

Target Audience 2025

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies